{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:34:55Z","timestamp":1793975695007,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269977"],"award-info":[{"award-number":["R01CA269977"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00848-4","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:01:20Z","timestamp":1731924080000},"page":"1885-1901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-2936","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Badura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Delavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Egusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Swinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8628-9698","authenticated-orcid":false,"given":"Haolong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6294","authenticated-orcid":false,"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-7878","authenticated-orcid":false,"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-7687","authenticated-orcid":false,"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-0391","authenticated-orcid":false,"given":"Jonathan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2117","authenticated-orcid":false,"given":"Lixing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cell.2013.04.010","volume":"153","author":"L Yang","year":"2013","unstructured":"Yang, L. et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153, 919\u2013929 (2013).","journal-title":"Cell"},{"key":"848_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112\u2013121 (2020).","journal-title":"Nature"},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-pathol-012615-044446","volume":"11","author":"J-K Lee","year":"2016","unstructured":"Lee, J.-K., Choi, Y.-L., Kwon, M. & Park, P. J. Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies. Annu. Rev. Pathol. 11, 283\u2013312 (2016).","journal-title":"Annu. Rev. Pathol."},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"848_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature10909","volume":"484","author":"O Hakim","year":"2012","unstructured":"Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 484, 69\u201374 (2012).","journal-title":"Nature"},{"key":"848_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jama.1997.03540360065034","volume":"277","author":"W Burke","year":"1997","unstructured":"Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277, 997\u20131003 (1997).","journal-title":"JAMA"},{"key":"848_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of Poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard, H., Garc\u00eda-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276\u2013280 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 10, 425\u2013448 (2015).","journal-title":"Annu. Rev. Pathol."},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.91.11.5124","volume":"91","author":"NC Denko","year":"1994","unstructured":"Denko, N. C., Giaccia, A. J., Stringer, J. R. & Stambrook, P. J. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc. Natl Acad. Sci. USA 91, 5124\u20135128 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1097-2765(02)00520-8","volume":"9","author":"O Vafa","year":"2002","unstructured":"Vafa, O. et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031\u20131044 (2002).","journal-title":"Mol. Cell"},{"key":"848_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton, C. J. et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature25507","volume":"555","author":"M Macheret","year":"2018","unstructured":"Macheret, M. & Halazonetis, T. D. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature 555, 112\u2013116 (2018).","journal-title":"Nature"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cell.2017.07.043","volume":"170","author":"S Hamperl","year":"2017","unstructured":"Hamperl, S., Bocek, M. J., Saldivar, J. C., Swigut, T. & Cimprich, K. A. Transcription-replication conflict orientation modulates R-loop levels and activates distinct DNA damage responses. Cell 170, 774\u2013786.e19 (2017).","journal-title":"Cell"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrm.2016.88","volume":"17","author":"T Garc\u00eda-Muse","year":"2016","unstructured":"Garc\u00eda-Muse, T. & Aguilera, A. Transcription-replication conflicts: how they occur and how they are resolved. Nat. Rev. Mol. Cell Biol. 17, 553\u2013563 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"848_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.molcel.2011.10.013","volume":"44","author":"A Helmrich","year":"2011","unstructured":"Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966\u2013977 (2011).","journal-title":"Mol. Cell"},{"key":"848_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nature18316","volume":"535","author":"TS Sankar","year":"2016","unstructured":"Sankar, T. S., Wastuwidyaningtyas, B. D., Dong, Y., Lewis, S. A. & Wang, J. D. The nature of mutations induced by replication-transcription collisions. Nature 535, 178\u2013181 (2016).","journal-title":"Nature"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.aba7408","volume":"373","author":"VB Seplyarskiy","year":"2021","unstructured":"Seplyarskiy, V. B. et al. Population sequencing data reveal a compendium of mutational processes in the human germ line. Science 373, 1030\u20131035 (2021).","journal-title":"Science"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","volume":"50","author":"G Macintyre","year":"2018","unstructured":"Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262\u20131270 (2018).","journal-title":"Nat. Genet."},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984\u2013991 (2022).","journal-title":"Nature"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41586-022-04789-9","volume":"606","author":"RM Drews","year":"2022","unstructured":"Drews, R. M. et al. A pan-cancer compendium of chromosomal instability. Nature 606, 976\u2013983 (2022).","journal-title":"Nature"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s43018-022-00404-y","volume":"3","author":"L Bao","year":"2022","unstructured":"Bao, L., Zhong, X., Yang, Y. & Yang, L. Starfish infers signatures of complex genomic rearrangements across human cancers. Nat. Cancer 3, 1247\u20131259 (2022).","journal-title":"Nat. Cancer"},{"key":"848_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"PJ Campbell","year":"2020","unstructured":"Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"},{"key":"848_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"848_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s43018-020-0050-6","volume":"1","author":"E Pleasance","year":"2020","unstructured":"Pleasance, E. et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat. Cancer 1, 452\u2013468 (2020).","journal-title":"Nat. Cancer"},{"key":"848_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100179","volume":"2","author":"SMA Islam","year":"2022","unstructured":"Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2, 100179 (2022).","journal-title":"Cell Genom."},{"key":"848_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccell.2018.06.008","volume":"34","author":"F Menghi","year":"2018","unstructured":"Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197\u2013210.e5 (2018).","journal-title":"Cancer Cell"},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1101\/gr.141382.112","volume":"23","author":"Y Drier","year":"2013","unstructured":"Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228\u2013235 (2013).","journal-title":"Genome Res."},{"key":"848_CR30","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1158\/0008-5472.CAN-15-2128","volume":"76","author":"T Popova","year":"2016","unstructured":"Popova, T. et al. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 76, 1882\u20131891 (2016).","journal-title":"Cancer Res."},{"key":"848_CR31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770\u20131782.e14 (2018).","journal-title":"Cell"},{"key":"848_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433\u2013447.e19 (2018).","journal-title":"Cell"},{"key":"848_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769.e9 (2018).","journal-title":"Cell"},{"key":"848_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nature24477","volume":"551","author":"NA Willis","year":"2017","unstructured":"Willis, N. A. et al. Mechanism of tandem duplication formation in BRCA1-mutant cells. Nature 551, 590\u2013595 (2017).","journal-title":"Nature"},{"key":"848_CR35","doi-asserted-by":"publisher","first-page":"26823","DOI":"10.1073\/pnas.1911584116","volume":"116","author":"X Fu","year":"2019","unstructured":"Fu, X. et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc. Natl Acad. Sci. USA 116, 26823\u201326834 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"848_CR36","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1093\/nar\/gkaa514","volume":"48","author":"M Tellier","year":"2020","unstructured":"Tellier, M. et al. CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation. Nucleic Acids Res. 48, 7712\u20137727 (2020).","journal-title":"Nucleic Acids Res."},{"key":"848_CR37","doi-asserted-by":"publisher","first-page":"e47592","DOI":"10.15252\/embr.201847592","volume":"20","author":"AP Chirackal Manavalan","year":"2019","unstructured":"Chirackal Manavalan, A. P. et al. CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep. 20, e47592 (2019).","journal-title":"EMBO Rep."},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1101\/gad.231274.113","volume":"28","author":"L Davidson","year":"2014","unstructured":"Davidson, L., Muniz, L. & West, S. 3\u2032 end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. Genes Dev. 28, 342\u201356 (2014).","journal-title":"Genes Dev."},{"key":"848_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molcel.2019.01.024","volume":"73","author":"MP Crossley","year":"2019","unstructured":"Crossley, M. P., Bocek, M. & Cimprich, K. A. R-loops as cellular regulators and genomic threats. Mol. Cell 73, 398\u2013411 (2019).","journal-title":"Mol. Cell"},{"key":"848_CR40","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.molcel.2022.04.014","volume":"82","author":"JR Brickner","year":"2022","unstructured":"Brickner, J. R., Garzon, J. L. & Cimprich, K. A. Walking a tightrope: the complex balancing act of R-loops in genome stability. Mol. Cell 82, 2267\u20132297 (2022).","journal-title":"Mol. Cell"},{"key":"848_CR41","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.cell.2016.09.053","volume":"167","author":"S Hamperl","year":"2016","unstructured":"Hamperl, S. & Cimprich, K. A. Conflict resolution in the genome: how transcription and replication make it work. Cell 167, 1455\u20131467 (2016).","journal-title":"Cell"},{"key":"848_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442\u2013451 (2013).","journal-title":"Cell"},{"key":"848_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anti-cancer potential of non-oncology drugs bysystematic viability profiling. Nat. Cancer 1, 235\u2013248 (2020).","journal-title":"Nat. Cancer"},{"key":"848_CR44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson, C. J., Backos, D. S. & Reigan, P. Targeting WEE1 kinase in cancer. Trends Pharmacol. Sci. 37, 872\u2013881 (2016).","journal-title":"Trends Pharmacol. Sci."},{"key":"848_CR45","doi-asserted-by":"publisher","first-page":"23891","DOI":"10.1073\/pnas.1915108116","volume":"116","author":"TN Moiseeva","year":"2019","unstructured":"Moiseeva, T. N., Qian, C., Sugitani, N., Osmanbeyoglu, H. U. & Bakkenist, C. J. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells. Proc. Natl Acad. Sci. USA 116, 23891\u201323893 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"848_CR46","doi-asserted-by":"publisher","first-page":"e101284","DOI":"10.15252\/embj.2018101284","volume":"38","author":"MA Gonz\u00e1lez Besteiro","year":"2019","unstructured":"Gonz\u00e1lez Besteiro, M. A. et al. Chk1 loss creates replication barriers that compromise cell survival independently of excess origin firing. EMBO J. 38, e101284 (2019).","journal-title":"EMBO J."},{"key":"848_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01401-x","volume":"8","author":"T Moiseeva","year":"2017","unstructured":"Moiseeva, T. et al. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat. Commun. 8, 1392 (2017).","journal-title":"Nat. Commun."},{"key":"848_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y. & Ashworth, A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10, 351\u2013370 (2020).","journal-title":"Cancer Discov."},{"key":"848_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.cell.2015.12.050","volume":"164","author":"NJ Haradhvala","year":"2016","unstructured":"Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538\u2013549 (2016).","journal-title":"Cell"},{"key":"848_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature13374","volume":"511","author":"V Bhatia","year":"2014","unstructured":"Bhatia, V. et al. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511, 362\u2013365 (2014).","journal-title":"Nature"},{"key":"848_CR51","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.molcel.2015.01.011","volume":"57","author":"E Hatchi","year":"2015","unstructured":"Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636\u2013647 (2015).","journal-title":"Mol. Cell"},{"key":"848_CR52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury, S. J., Boutz, P. L. & Sharp, P. A. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564, 141\u2013145 (2018).","journal-title":"Nature"},{"key":"848_CR53","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","volume":"30","author":"CB Nguyen","year":"2024","unstructured":"Nguyen, C. B. et al. Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial. Clin. Cancer Res. 30, 3200\u20133210 (2024).","journal-title":"Clin. Cancer Res."},{"key":"848_CR54","doi-asserted-by":"publisher","unstructured":"Chou, J. et al. Synthetic lethal targeting of cyclin dependent kinase-12-deficient prostate cancer with PARP inhibitors. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3785 (2024).","DOI":"10.1158\/1078-0432.CCR-23-3785"},{"key":"848_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"848_CR56","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1128\/MCB.06267-11","volume":"32","author":"S-WG Cheng","year":"2012","unstructured":"Cheng, S.-W. G. et al. Interaction of cyclin-dependent kinase 12\/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol. Cell. Biol. 32, 4691\u20134704 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"848_CR57","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","volume":"82","author":"PC O\u2019Leary","year":"2022","unstructured":"O\u2019Leary, P. C. et al. Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2. Cancer Res. 82, 3950\u20133961 (2022).","journal-title":"Cancer Res."},{"key":"848_CR58","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"848_CR59","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"848_CR60","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"848_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"848_CR62","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"848_CR63","doi-asserted-by":"publisher","unstructured":"Sasaki, T. Public data files from legacy Replicationdomain.com. figshare https:\/\/doi.org\/10.6084\/m9.figshare.26914816.v3 (2024).","DOI":"10.6084\/m9.figshare.26914816.v3"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00848-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:05:45Z","timestamp":1734912345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00848-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00848-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A. reports personal fees from Tango Therapeutics, Azkarra Therapeutics, Ovibio, Kytarro, CytomX, Cambridge Science Corporation, Genentech, Gladiator, Circle, Bluestar, Earli, Ambagon, Trial Library, Phoenix Molecular Designs, GSK, Prolynx; grants from SPARC and AstraZeneca outside the submitted work. In addition, he holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). F.Y.F. reports personal fees from Bluestar Genomics, Astellas, Foundation Medicine, Exact Sciences, Tempus, POINT Biopharma, Janssen, Bayer, Myovant, Roivant, SerImmune, Bristol Myers Squibb and Novartis, and personal fees from POINT Biopharma outside the submitted work and other support from Artera. J.C. reports consulting fees from Exai Bio outside the submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}